Dr. Margaret Hahn, MD, PhD
Claim this profileCenter for Addiction and Mental Health
Studies Schizophrenia
Studies Psychosis Prodrome
4 reported clinical trials
6 drugs studied
Affiliated Hospitals
Clinical Trials Margaret Hahn, MD, PhD is currently running
Semaglutide
for Schizophrenia and Obesity
This trial is testing a medication to help overweight or obese patients with schizophrenia who are on antipsychotics and haven't lost enough weight with metformin. The medication works by making you feel full sooner and helping your body use insulin better. It has been shown to induce significant weight loss in individuals with obesity or overweight.
Recruiting0 awards N/A4 criteria
Intranasal Insulin + Olanzapine
for Healthy Volunteers
Antipsychotic (AP) medications are considered to be the gold standard treatment for psychotic disorders including schizophrenia. However, APs have also been commonly associated with serious metabolic adverse effects including weight gain and Type 2 Diabetes, with younger populations disproportionately affected. In addition, young individuals treated with these agents have also been found to be at high risk for glucose dysregulation, including higher rates of prediabetes, with significant associations found between AP use and insulin resistance. Due to the concerning prevalence of these AP metabolic effects, it becomes important to further elucidate the mechanisms underlying AP effects on glucose metabolism, which are still poorly understood. One potential underlying mechanism is insulin which has been found to regulate hepatic (liver) glucose production through insulin receptors in the brain. These insulin receptors also play a role in neuronal growth and memory, or more broadly, cognition. Preliminary data in rat models has demonstrated that the AP olanzapine (OLA) inhibits the ability of a central insulin stimulus (acting at the level of the brain) to decrease endogenous glucose production (EGP), making this mechanism a prime target to translate from rodent models to human research. Furthermore, intranasal insulin (INI) administration (an analogous central insulin stimulus) has been repeatedly associated with improved cognitive performance for verbal memory and visuospatial functions in humans. Given these findings and with the goal of translational research, the present study will investigate OLA's effects in healthy human volunteers including: (a) the ability of INI to reduce EGP during a pancreatic euglycemic clamp (PEC; a glucose metabolism and insulin procedure); and (b) the ability of INI to improve cognitive performance. More specifically, the present study hypothesizes that: 1. INI will be associated with a decrease in EGP relative to intranasal placebo (INP) as measured by the PEC. This effect will be inhibited if OLA is co-administered. 2. OLA administration will be associated with decrements in cognitive measures (i.e., visuospatial, and verbal memory) as compared to placebo (PL). Additionally, OLA co-administration will block the beneficial effects of INI on cognition previously supported by other studies. 3. INI will result in adaptive changes in neurochemical and neurohemodynamic measures as studied using MRI imaging techniques.
Recruiting2 awards Phase 13 criteria
More about Margaret Hahn, MD, PhD
Clinical Trial Related2 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Margaret Hahn, MD, PhD has experience with
- Placebo
- Semaglutide
- Intranasal Insulin
- Olanzapine
- Topiramate
- Observation
Breakdown of trials Margaret Hahn, MD, PhD has run
Schizophrenia
Psychosis Prodrome
Healthy Controls
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Margaret Hahn, MD, PhD specialize in?
Margaret Hahn, MD, PhD focuses on Schizophrenia and Psychosis Prodrome. In particular, much of their work with Schizophrenia has involved treating patients, or patients who are undergoing treatment.
Is Margaret Hahn, MD, PhD currently recruiting for clinical trials?
Yes, Margaret Hahn, MD, PhD is currently recruiting for 3 clinical trials in Toronto Ontario. If you're interested in participating, you should apply.
Are there any treatments that Margaret Hahn, MD, PhD has studied deeply?
Yes, Margaret Hahn, MD, PhD has studied treatments such as Placebo, Semaglutide, Intranasal Insulin.
What is the best way to schedule an appointment with Margaret Hahn, MD, PhD?
Apply for one of the trials that Margaret Hahn, MD, PhD is conducting.
What is the office address of Margaret Hahn, MD, PhD?
The office of Margaret Hahn, MD, PhD is located at: Center for Addiction and Mental Health, Toronto, Ontario M5T 1R8 Canada. This is the address for their practice at the Center for Addiction and Mental Health.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.